Blueprint Medicines Corp
BPMCDelisted Jul 18, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597264
Blueprint Medicines Corp was delisted on Jul 18, 2025; its insiders filed their last Form 4 on Jul 21, 2025; 356 institutions reported holding it in 13F filings for Q2 2025, worth $8.65B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 356
- Q2 2025, +4 vs. previous quarter
- 13F value
- $8.65B
- Reported value at the end of Q2 2025
- Superinvestors holding
- 1
- At the end of Q2 2025
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2024
- $508.8M
- +104.0% year over year
- Net income, FY2024
- -$67.1M
- No comparable prior period
- Free cash flow, FY2024
- -$197.2M
- No comparable prior period
- Revenue, Q1 FY2025
- $149.4M
- +55.5% year over year
Superinvestors holding BPMC, Q2 2025
Go to the superinvestors tab1 superinvestor reports holding Blueprint Medicines Corp on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.5%
Blueprint Medicines Corp's share of the portfolio
- Shares
- 250,000
- Value
- $32.0M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Blueprint Medicines Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −1.17K | $128.25 | −$150.3K | −1.8%63.5K after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Carter Percy H.CHIEF SCIENTIFIC OFFICER | SSale | −1.05K | $128.25 | −$134.8K | −1.9%53.2K after | |
| Jun 5, 2025 (view filing) | Jun 3 | 2 days | Carter Percy H.CHIEF SCIENTIFIC OFFICER | SSale | −2.66K | $127.88 | −$340.0K | −4.7%54.2K after | 2 lots |
| May 29, 2025 (view filing) | May 27 | 2 days | Albers Jeffrey W.Director | SSale | −5.00K | $101.14 | −$505.7K | −3.3%146.6K after | 2 lots10b5-1 |
| May 21, 2025 (view filing) | May 19 | 2 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −2.27K | $100.51 | −$228.6K | −3.4%64.7K after | 3 lots10b5-1 |
| May 7, 2025 (view filing) | May 5 | 2 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −2.27K | $101.75 | −$231.4K | −3.3%67.0K after | 4 lots10b5-1 |
| May 7, 2025 (view filing) | May 5 | 2 days | Hurley ArielPRINCIPAL ACCOUNTING OFFICER | SSale | −2.75K | $103.13 | −$283.8K | −14.0%16.9K after | 3 lots10b5-1 |
| Apr 3, 2025 (view filing) | Apr 1 | 2 days | Haviland KateCHIEF EXECUTIVE OFFICER | SSale | −2.50K | $86.65 | −$216.5K | −1.5%165.9K after | 4 lots10b5-1 |
| Mar 26, 2025 (view filing) | Mar 24 | 2 days | Rossi ChristinaCHIEF OPERATING OFFICER | SSale | −2.27K | $95.02 | −$216.1K | −3.2%69.3K after | 10b5-1 |
| Mar 17, 2025 (view filing) | Mar 5 | 12 daysLate | Albers Jeffrey W.Director | SSale | −5.77K | $88.80 | −$512.0K | −3.8%146.6K after |
Top 10 13F holders, Q2 2025
See all 356 holdersThe largest institutional positions in Blueprint Medicines Corp at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 6,416,603 | $822.5M | 0.01% | −223,920−3.4% | Reduced |
| BlackRock, Inc. | 6,118,428 | $784.3M | 0.02% | −592,280−8.8% | Reduced |
| Pentwater Capital Management LP | 3,900,000 | $499.9M | 6.38% | +3,900,000 | New |
| HBK Investments L P | 3,200,924 | $410.3M | 7.29% | +3,200,924 | New |
| State Street Corp | 2,230,980 | $286.0M | 0.01% | −453,137−16.9% | Reduced |
| UBS Group AG | 2,167,028 | $277.8M | 0.06% | +1,953,223+913.6% | Added |
| FIL Ltd | 1,759,500 | $225.5M | 0.19% | +1,759,500 | New |
| UBS Oconnor LLC | 1,713,587 | $219.6M | 6.00% | +1,698,722+11,427.7% | Added |
| Barclays PLC | 1,556,918 | $199.6M | 0.08% | +1,427,323+1,101.4% | Added |
| Geode Capital Management, LLC | 1,541,013 | $197.6M | 0.01% | +18,366+1.2% | Added |
Holders of 5% or more of BPMC
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Blueprint Medicines Corp.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.00%5.09M shares | – | Apr 23, 20251 filing | Apr 23, 2025 | SEC |
| Pentwater Capital Management LP | 13G | 6.00%3.90M shares | New | Aug 14, 20251 filing | Aug 14, 2025 | SEC |